Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria | NEJM - nejm.org

Original Article from The New England Journal of Medicine — Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

Trial Design and Participants VRC 614 was a phase 1, open-label, dose-escalation clinical trial. The primary objectives of the trial were to evaluate the safety and side-effect profile of L9LS admin… [+6626 chars]

full article...